These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37462850)

  • 1. Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis.
    Leclercq M; Goupillou P; Gomez H; Muraine M; Benhamou Y; Girszyn N; Gueudry J
    J Ophthalmic Inflamm Infect; 2023 Jul; 13(1):32. PubMed ID: 37462850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report.
    Burlo F; Tumminelli C; Pastore S; Stocco G; Curci D; Lucafò M; Tommasini A; Taddio A
    Pediatr Rheumatol Online J; 2023 Sep; 21(1):99. PubMed ID: 37700264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.
    Mesquida M; Molins B; Llorenç V; Sainz de la Maza M; Adán A
    Ophthalmology; 2014 Dec; 121(12):2380-6. PubMed ID: 25204610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis.
    Maleki A; Manhapra A; Asgari S; Chang PY; Foster CS; Anesi SD
    Ocul Immunol Inflamm; 2021 Jan; 29(1):14-20. PubMed ID: 33021415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
    Vegas-Revenga N; Calvo-Río V; Mesquida M; Adán A; Hernández MV; Beltrán E; Valls Pascual E; Díaz-Valle D; Díaz-Cordovés G; Hernandez-Garfella M; Martínez-Costa L; Calvo I; Atanes A; Linares LF; Modesto C; González-Vela C; Demetrio-Pablo R; Aurrecoechea E; Cordero M; Domínguez-Casas LC; Atienza-Mateo B; Martín-Varillas JL; Loricera J; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
    Am J Ophthalmol; 2019 Apr; 200():85-94. PubMed ID: 30660771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases.
    Silpa-Archa S; Oray M; Preble JM; Foster CS
    Acta Ophthalmol; 2016 Sep; 94(6):e400-6. PubMed ID: 27010181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Subcutaneous and Intravenous Tocilizumab in Noninfectious Uveitis.
    Kherani S; Alapati A; Begaj T; Atlas S; Koreishi A; Janetos T; Faia LJ; Goldstein DA
    Ophthalmology; 2024 Oct; ():. PubMed ID: 39419184
    [No Abstract]   [Full Text] [Related]  

  • 8. Tocilizumab in severe and refractory non-infectious uveitis.
    Papo M; Bielefeld P; Vallet H; Seve P; Wechsler B; Cacoub P; Le Hoang P; Papo T; Bodaghi B; Saadoun D
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S75-9. PubMed ID: 25268663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study.
    Darloy J; Segaud N; Salmon JH; Eschard JP; Goëb V; Deprez X; Guyot MH; Houvenagel E; Lecuyer N; Marguerie L; Gally S; Pau D; Idier I; Baudens G; Flipo RM
    Rheumatol Ther; 2019 Mar; 6(1):61-75. PubMed ID: 30632015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.
    Sepah YJ; Sadiq MA; Chu DS; Dacey M; Gallemore R; Dayani P; Hanout M; Hassan M; Afridi R; Agarwal A; Halim MS; Do DV; Nguyen QD
    Am J Ophthalmol; 2017 Nov; 183():71-80. PubMed ID: 28887113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.
    Muselier A; Bielefeld P; Bidot S; Vinit J; Besancenot JF; Bron A
    Ocul Immunol Inflamm; 2011 Oct; 19(5):382-3. PubMed ID: 21970668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in Large Vessel Vasculitis - Different Routes of Administration.
    Schmalzing M; Gadeholt O; Gernert M; Tony HP; Schwaneck EC
    Open Rheumatol J; 2018; 12():152-159. PubMed ID: 30258504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Sainz de la Maza M; Adán A
    Retina; 2018 Jul; 38(7):1361-1370. PubMed ID: 28520640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond.
    Karkhur S; Hasanreisoglu M; Vigil E; Halim MS; Hassan M; Plaza C; Nguyen NV; Afridi R; Tran AT; Do DV; Sepah YJ; Nguyen QD
    J Ophthalmic Inflamm Infect; 2019 Sep; 9(1):17. PubMed ID: 31523783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis.
    Wennink RAW; Ayuso VK; de Vries LA; Vastert SJ; de Boer JH
    Ocul Immunol Inflamm; 2021 Jan; 29(1):21-25. PubMed ID: 32058831
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis.
    Hassan M; Nguyen NV; Halim MS; Afridi R; Sadiq MA; Karkhur S; Vigil E; Karabekirogullari S; Nguyen QD; Do DV; Sepah YJ;
    J Ophthalmic Inflamm Infect; 2019 Jul; 9(1):12. PubMed ID: 31325001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab treatment for refractory uveitis-related cystoid macular edema.
    Adán A; Mesquida M; Llorenç V; Espinosa G; Molins B; Hernández MV; Pelegrín L
    Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2627-32. PubMed ID: 23893042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
    Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
    Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.